Andrej Dukát

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

John J.V. McMurray, Scott D. Solomon, Silvio E. Inzucchi et al. · New England Journal of Medicine · 2019 · 6.9K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

Milton Packer, John J.V. McMurray, Akshay S. Desai et al. · Circulation · 2014 · 667 citations · Full text

Medicine, Cardiology, Pharmacology +16

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study

Luís M. Ruilope, Andrej Dukát, Michael Böhm et al. · The Lancet · 2010 · 592 citations

Medicine, Pharmacology, Pharmacotherapy +17

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction

Scott D. Solomon, Brian Claggett, Akshay S. Desai et al. · Circulation Heart Failure · 2016 · 210 citations

Medicine, Pharmacology, Pharmacotherapy +16